Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Bristol-Myers Squibb continued its immuno-therapy march today with a combo approval in melanoma. The pairing of its older med Yervoy and new PD-1 cancer-fighter Opdivo won the FDA's green light for patients with advanced melanoma and a particular genetic variation.
Turns out, pharmacy benefits managers are doing fine at controlling their costs for the new generation of cholesterol drugs. How? By limiting scripts to patients who are actually eligible for the PCSK9 meds, which carry list prices of more than $14,000.
The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster Gilenya, handing a win to challenger Torrent Pharmaceuticals--and fellow generics makers Mylan and Apotex, which had filed a separate challenge.
With pharma's U.S. pricing power apparently in jeopardy, industry watchers are worried. Just take a look at drug stocks' performance over the past week or so, as a firestorm over an enormous price increase by one drugmaker--Turing Pharmaceuticals--inspired political promises and public rancor.
What will Allergan look like after it hives off its generics unit to Teva Pharmaceutical Industries? The company unveiled some new numbers on that score Monday. And while the company's status as a potential top 10 pharma company proved short-lived, it's still looking for a growth rate that outpaces its Big Pharma peers.
Pfizer CEO Ian Read isn't too worried about proposals to crack down on U.S. drug pricing. Presidential candidate Hillary Clinton's slate of new measures--which include negotiating power for Medicare--aren't likely to pass muster in Congress, Read told Evercore ISI analyst Mark Schoenebaum.
Sanofi has put off one biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering Lantus SoloStar, the injectable pen version of Sanofi's basal insulin.
Cleared for liftoff on Friday alongside a combo drug, Ryzodeg, Novo Nordisk's Tresiba can now go up against Sanofi's Toujeo, armed with a raft of data on its heart safety. But one area where Novo doesn't plan to compete with Toujeo--at least not publicly--is on price.
One of pharma's key strategies for growing a drug's sales is expanding into bigger groups of patients. Thing is, the BMJ contends, those follow-up studies are often less stringent than they should be.
Amid all the drug-pricing brouhaha this week, a British pharmacologist was preparing to unveil his research showing just how much more Americans pay for cancer therapies. And while it's well known that medications cost more in the U.S. than in other countries, this new study puts some surprising numbers to that spread.